1FDA Approves Tykerb for Advanced Breast Cancer Patients[ EB/ OL]. FDA News P0744, March 13, 2007. http://www, fda. gov/bbs/topics/N EWS/2007/NEW01586. html.
2Glaxo Smith Kline. Highlights of Prescribing Information:TYKERB (lapatinb) tables [ J/OL ]. http://www, fda. gov/cder/ foi/label/2007 /0220591bl. pdf.
3JOHNSTON S R, I,EARY A. Lapatinib: a novrel EGFR/HER2 tyrosine kinase inhibitor for cancer [ J ] . Drugs 7bday (Barc ), 2006,42(7) :441-453.
4GEYER C E, FORSTER J, LINDQUIST D, et al. Lapatinib plus capecitabine for ltER2-positive advanced breast cancer [ J ]. N Engl J Med,2006,355 (26) :2733-2743.
5NAHTA R, YUAN L X, DU Y, et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulinlike growth factor I signaling [ J ]. Mol Cancer Tiger,2007,6 (2) : 667-674.
6KONECNY G E, PEGRAM M D, VENKATESAN N, et al. Activity of the dual kinase inhibitor lapatinib ( GW572016 ) against HER-2-overexpressing and trastuzumab-treated breast cancer cells [ J ]. Cancer Res ,2006,66 ( 3 ) : 1630-1639.
7KELLY H, GRAHAM M, HUMES E, et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinlb [ J ]. Clln Breast Cancer,200,7(4) :339-341.
4GAUTAM A P, FERNANDES D J, VIDYASAGAR M S, et al. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy-a randomized controlled trial [J]. Support Care Cancer, 2013, 21(5): 1421-1428.
5SATHEESHKUMAR P S, MOHAN M P. Tachykinin peptide, substance P, and its receptor NK-1R play an important role in alimentary tract mucosal inflammation during cytotoxic therapy [J]. Dig Dis Sci, 2014, 59(12): 2864-2873.
6UANTAM A P, FERMANDES D J, VIDYASAGER M S, et al. Effect of low level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receivin chemoradiotherapy-a randomized controlled trial [J]. Support Care Cancer, 2013, 21(5): 1421-1428.
7FUKAZAWA M, KAWAGUCHI H, SHIGEMATSU H, et al. High incidencerate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy(FEClO0) [J]. Gan To Kagaku Ryoho, 2012, 39(3): 395-398.
8RICCI F, PARADISI A, SILVERI S L, et al. Adverse skin reactions during treatment with cetuximab plus radiotherapy: multidisciplinary approach to minimise radio-chemotherapy interruption [J]. J Dermatol Treat, 2014, 26(2): 1-20.
9EPPERLY M W, FRANICOLA D, ZHANG X, et al. Effect of EGFR antagonists gefitinib (iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line [J]. Vivo, 2006, 20(68): 791-796.
10BERG E A, PLATTS-MILLS T A, COMMINS S P. Drug allergens and food-the cetuximab and galaetose-a-1,3- galactose story [J]. Ann Allergy Ashma Immunol, 2014, 112(2): 97-101.
